nuclear-medicine-radiation-therapy-2018-tracks

3 / 20

Page 23
Journal of Medical Physics and Applied Sciences
ISSN: 2574-285X
I n t e r n a t i o n a l C o n f e r e n c e o n
Nuclear Medicine &
Radiation Therapy
Nuclear Medicine & Radiation Therapy 2018
O c t o b e r 0 1 - 0 2 , 2 0 1 8
S t o c k h o l m , S w e d e n
Biography
Marcel Stokkel is a Nuclear Medicine Physician since 1997 and
has completed his PhD in 1999. He is Head of the Department
of Nuclear Medicine and Head of the division of Diagnostic On-
cology of the Netherlands Cancer Insititute–Antoni van Leeu-
wenhoek Hosptial. In addition, he is Chair of the Netherlands
Society of Nuclear Medicine. He has published almost 200 pa-
pers in reputed journals and has been serving as an Editorial
Board Member of repute.
The role of nuclear medicine in prostate cancer imaging,
treatment and surgery
Marcel P M Stokkel, Judith Olde Heuvel and Linda de Wit van de Veen
Netherlands Cancer Institute, The Netherlands
Marcel P M Stokkel et al., J. med phys & appl sci 2018, Volume: 3
DOI: 10.21767/2574-285X-C1-002
Over the past year, prostate cancer imaging and stagingwithgallium-68prostate
specific membrane antigen (68Ga-PSMA) PET/CT has been introduced in
clinical practice. The higher sensitivity and specificity compared with C11-choline
or other tracers even at low PSA levels have been shown in many papers. Also
in high risk patients, 68 Ga-PSMA PET/CT is increasingly used demonstrating
additional value prior to surgery. Although the additional value still has to be
established, its role in oncological setting is growing. The same carrier (PSMA)
can be used in clinical practice for hormone refractory prostate cancer treatment
by labelling it with lutethium-177 (177Lu), a beta-emitting radionuclide. An overview
will be given on the diagnostic and therapeutic value in prostate cancer. A new
application 68Ga-PSMA, the intra-operative evaluation of prostatectomy margins,
has recently been granted by KWF-STW. This evaluation is based on the emission
of Cerenkov light, which is a side-effect of the emission of protons from 68Ga. This
blue light is emitted from tumors that are not completely resected during surgery,
whereas in radically resected tumors this light will be attenuated from normal
tissue surrounding the primary tumor. A technical evaluation of this technique
is presented and the introduction into clinical practice is described. The latest
development in image guided surgery is the introduction of technetium-99m
PSMA (99 mTc-PSMA). By using this technique, it might become possible to pre-
operatively image prostate cancer metastases in loco-regional lymph nodes and
to detect these nodes during surgery using standard probes. It is expected to gain
a role in lymph node metastases with a diameter >5mm. In smaller lesions, its role
is not clear yet. In this respect, a standard sentinel node procedure is available to
image and detect lymph nodes at risk for metastatic disease. All procedures will
be discussed during this presentation, high lighting the increasing role of nuclear
medicine in cancer staging and treatment.